Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP05 3.2 g/day vs mesalazine for treatment of active ulcerative colitis
2013-000366-11Phase 3Completed
- Sponsor
- Tillotts Pharma AG
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Tillotts Pharma AG. Primary endpoint: Primary efficacy endpoint. Started May 2013; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-000366-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000366-11.